Hygrolidin

BIOLOGICAL ACTIV	ITV	
Description	Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti- fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity ^{[1][2][3]} .	
IC ₅₀ & Target	Macrolide	
In Vitro	 Hygrolidin (0.1, 1 μg/ml; for 24 h) increases both G1 and S phase populations and decreases M phase population^[1]. Hygrolidin (0.1, 1, 10 μg/ml; for 24 h) decreases the amounts of cdk4, cyclin D, cyclin B and increases the amounts of cyclin E and p21. Hygrolidin-induced p21 preferentially associates with cyclin A-cdk2 complex and inhibits it^[1]. Hygrolidin (0.1, 1 μg/ml; for 24 h) selectively induces p21 in DLD-1 cells at mRNA level, but not in WI-38 fibroblasts^[1]. Hygrolidin, for 3 days, inhibits growth of various cell lines including DLD-1 colon cancer, LNCaP prostate cancer, K562 leukemia cells, LNCaP prostate cancer, EL-4 lymphoma (IC₅₀ = 1.0-33 ng/ml, respectively)^[1]. Hygrolidin shows growth inhibition on Trypanosoma cruzi (IC₅₀=1.1 nM), Trypanosoma brucei brucei (IC₅₀=77 nM), and Leishmania donovani (IC₅₀=72.5 nM)^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle Analysis^[1] 	
	Cell Line:	DLD-1 cells
	Concentration:	0.1, 1 μg/ml
	Incubation Time:	For 24 hours
	Result:	Increased both G1 and S phase populations and decreased M phase population.
	Western Blot Analysis ^[1]	
	Cell Line:	DLD-1 cells
	Concentration:	0.1, 1, 10 μg/ml
	Incubation Time:	For 24 hours
	Result:	Decreased the amounts of cdk4, cyclin D, cyclin B and increased the amounts of cyclin E and p21.



®

Product Data Sheet

RT-PCR ^[1]	
Cell Line:	DLD-1 or WI-38 cells
Concentration:	0.1, 1 μg/ml
Incubation Time:	For 24 hours
Result:	Selectively induced p21 in DLD-1 cells at mRNA level, but not in WI-38 fibroblasts.

REFERENCES

[1]. Manabu Kawada, et al. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Biochem Biophys Res Commun. 2002 Oct 18;298(1):178-83.

[2]. H Seto, et al. The isolation and structures of hygrolidin amide and defumarylhygrolidin. J Antibiot (Tokyo). 1984 May;37(5):610-3.

[3]. F Annang, et al. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease. J Biomol Screen. 2015 Jan;20(1):82-91.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA